Inventor · disambiguated record
Tilman Schlothauer
Also filed as: SCHLOTHAUER TILMAN · SCHLOTHAUER TILMAN SEBASTIAN
31 granted patents·34 pending applications·333 citations·filing 2008–2025
96Inventor score
Top patents by PatentIndex Score
65 records- 0197US10323089B2Anti-transferrin receptor antibodies with tailored affinityHOFFMANN LA ROCHE·Filed 2017·Granted Jun 18, 2019·25 cites·9 claims
- 0297US8969526B2Antibody Fc variantsBAEHNER MONIKA·Filed 2012·Granted Mar 3, 2015·226 cites·8 claims
- 0396US10683368B2Fc-region variants with modified FcRn-binding and methods of useHOFFMANN LA ROCHE·Filed 2017·Granted Jun 16, 2020·13 cites·12 claims
- 0495US11584793B2Anti-transferrin receptor antibodies with tailored affinityHOFFMANN LA ROCHE·Filed 2019·Granted Feb 21, 2023·8 cites·20 claims
- 0595US11286300B2Humanized anti-human CD19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Mar 29, 2022·11 cites·8 claims
- 0694US12252533B2Anti-transferrin receptor antibodies with tailored affinityHOFFMANN LA ROCHE·Filed 2022·Granted Mar 18, 2025·1 cites·11 claims
- 0793US10011644B2Method for producing soluble FcR as Fc-fusion with inert immunoglobulin Fc-region and uses thereofHOFFMANN LA ROCHE·Filed 2015·Granted Jul 3, 2018·9 cites·3 claims
- 0891US10822402B2Humanized anti-tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2017·Granted Nov 3, 2020·4 cites·12 claims
- 0990US11091541B2Human FcRn-binding modified antibodies and methods of useHOFFMANN LA ROCHE·Filed 2015·Granted Aug 17, 2021·6 cites·7 claims
- 1090US10287352B2Bispecific antibodies specific for PD1 and TIM3HOFFMANN LA ROCHE·Filed 2016·Granted May 14, 2019·10 cites·21 claims
- 1189US11555067B2Fc-region variants with improved protein A-bindingHOFFMANN LA ROCHE·Filed 2019·Granted Jan 17, 2023·3 cites·8 claims
- 1289US11130810B2Bispecific antibodies specific for PD1 and TIM3HOFFMANN LA ROCHE·Filed 2019·Granted Sep 28, 2021·4 cites·36 claims
- 1387US10434184B2Anti-TPBG antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Oct 8, 2019·3 cites·22 claims
- 1486US11525007B2Antibody fab and Fc variantsHOFFMANN LA ROCHE·Filed 2018·Granted Dec 13, 2022·3 cites·5 claims
- 1585US9862763B2Humanized anti-tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Jan 9, 2018·4 cites·13 claims
- 1684US12297263B2Humanized anti-Tau(PS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Granted May 13, 2025·0 cites·6 claims
- 1784US2024018259A1Antibody fc variantsROCHE GLYCART AG·Filed 2023·Application pending·0 cites
- 1883US12264196B2Fc-receptor binding modified asymmetric antibodies and methods of useHOFFMANN LA ROCHE·Filed 2019·Granted Apr 1, 2025·1 cites·14 claims
- 1982US11739142B2Bispecific anti-CCL2 antibodiesHOFFMANN LA ROCHE·Filed 2020·Granted Aug 29, 2023·1 cites·2 claims
- 2082US2025376523A1Humanized anti-human cd19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2180US12398203B2Method for producing bispecific antibodies comprising a Y436A Fc-region mutation for improved protein A-bindingHOFFMANN LA ROCHE·Filed 2022·Granted Aug 26, 2025·0 cites·7 claims
- 2278US2022324955A1Fc-receptor binding modified asymmetric antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2377US12103967B2Bispecific anti-CCL2 antibodiesHOFFMANN LA ROCHE·Filed 2023·Granted Oct 1, 2024·0 cites·27 claims
- 2476US12215152B2Humanized anti-human CD19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Granted Feb 4, 2025·0 cites·8 claims
- 2574US10093714B1Method for producing soluble FcR as Fc-fusion with inert immunoglobulin Fc-region and uses thereofHOFFMANN LA ROCHE·Filed 2018·Granted Oct 9, 2018·1 cites·5 claims
- 2672US11572404B2Humanized anti-Tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Granted Feb 7, 2023·0 cites·6 claims
- 2772US2024047012A1Methods and systems for predicting function based on related biophysical attributes in data modelingGENENTECH INC·Filed 2023·Application pending·0 cites
- 2872US2024083993A1Bispecific anti-ccl2 antibodiesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 2971US2020172607A1Fc-receptor binding modified asymmetric antibodies and methods of useHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 3071US2025154249A1Anti-transferrin receptor antibodies with tailored affinityHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 3170US12391757B2Bispecific antibodies specific for PD1 and TIM3HOFFMANN LA ROCHE·Filed 2021·Granted Aug 19, 2025·0 cites·20 claims
- 3270US2025347690A1Ph-gradient spr-based binding assayHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 3369US2021139603A1Antibody fc variantsROCHE GLYCART AG·Filed 2020·Application pending·0 cites
- 3465US11814409B2Fc-receptor based affinity chromatographyHOFFMANN LA ROCHE·Filed 2019·Granted Nov 14, 2023·0 cites·16 claims
- 3565US2024019424A1Method for resolving complex, multistep antibody interactionsHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 3663US11440942B2Complement factor based affinity chromatographyHOFFMANN LA ROCHE·Filed 2019·Granted Sep 13, 2022·0 cites·12 claims
- 3763US2016068613A1Fc-receptor binding modified asymmetric antibodies and methods of useHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 3862US11440971B2Fc-region variants with modified FcRn-binding and methods of useHOFFMANN LA ROCHE·Filed 2020·Granted Sep 13, 2022·0 cites·12 claims
- 3961US2025093367A1Quantification of low amounts of antibody side-productsHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 4060US12461109B2Vitro prediction of in vivo half-lifeHOFFMANN LA ROCHE·Filed 2021·Granted Nov 4, 2025·0 cites·4 claims
- 4160US2021246228A1Fc-region variants with modified fcrn- and protein a-binding propertiesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 4259US2017044246A1Fc-region variants with improved protein a-bindingHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 4358US2021041163A1Method for selecting antibodies with modified fcrn interactionHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 4457US2008248510A1HUMAN Fc GAMMA RECEPTOR IIIBRINKMANN ULRICH·Filed 2008·Application pending·0 cites
- 4556US2017137530A1Antibody fc variantsROCHE GLYCART AG·Filed 2016·Application pending·0 cites
- 4656US2015018241A1Fc-receptor based affinity chromatographyHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 4756US2016194389A1Fc-receptor binding modified asymmetric antibodies and methods of useHOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
- 4856US2020108154A1Anti-tpbg antibodies and methods of useHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 4955US10899846B2Fc-region variants with modified FcRn- and protein A-binding propertiesHOFFMANN LA ROCHE·Filed 2017·Granted Jan 26, 2021·0 cites·22 claims
- 5055US2022099680A1Spr-based binding assay for the functional analysis of multivalent moleculesHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
Showing the top 50 of 65 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Tilman Schlothauer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →